Home - Products - Inhibitors & Agonists - Metabolic Enzyme/Protease Library - Details

Dovramilast (Synonyms: CC-11050) CAS No.: 340019-69-4

Chemical Structure : Dovramilast (Synonyms: CC-11050)
CAS No.: 340019-69-4

Send Inquiry

Description

Chemical Structure : Dovramilast (Synonyms: CC-11050)

CAS No.: 340019-69-4

Dovramilast (Synonyms: CC-11050)

Catalog No.: URK-V2485 Only Used For Lab.

Biological Activity

Dovramilast is a selective phosphodiesterase 4 (PDE4) inhibitor that works by blocking the enzyme PDE4, which is responsible for the breakdown of cyclic adenosine monophosphate (cAMP) in inflammatory cells.
Dovramilast has shown a potent anti-inflammatory effect in reducing symptoms such as coughing, wheezing, and shortness of breath in patients with asthma.
The unique mechanism of action of Dovramilast makes it a promising drug for the treatment of airway diseases. In addition, its oral administration and good safety profile make it an attractive option for long-term therapy.

Physicochemical Properties

M.Wt	472.55
Formula	C₂₄H₂₈N₂O₆S
CAS No.	340019-69-4
Appearance	Solid
Storage	Solide Powder -20 °C 3years; 4°C 2years	In Solvent -80°C 6 Months -20°C 1 Months
Solubility
Chemical Name

References

1. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.

2. Spina D. PDE4 inhibitors: current status and potential for the treatment of asthma. Drugs. 2008;68(5): 803–816.

3. Yamasaki K, Suzuki K, Ichinose M. Phosphodiesterase 4 inhibitors in the treatment of COPD and asthma: where are we now and where do we go from here? Pharmacol Ther. 2019;204:107398.